title: Does the PPAR-γ-activating property of telmisartan provide a benefit in clinical practice?
authors.forename: Akio
authors.initials: A
authors.lastname: Fujimura
authors.forename: Kentarou
authors.initials: K
authors.lastname: Ushijima
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Ando
mesh_terms: D047228:Angiotensin II Type 1 Receptor Blockers / Q000494:pharmacology / Q000627:therapeutic use; D001562:Benzimidazoles / Q000494:pharmacology / Q000627:therapeutic use*; D001565:Benzoates / Q000494:pharmacology / Q000627:therapeutic use*; D015897:Comorbidity; D003920:Diabetes Mellitus / Q000453:epidemiology* / Q000378:metabolism; D005947:Glucose / Q000378:metabolism; D006706:Homeostasis / Q000187:drug effects / Q000502:physiology; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000453:epidemiology*; D007328:Insulin / Q000097:blood; D047495:PPAR gamma / Q000819:agonists* / Q000187:drug effects; D000077333:Telmisartan; D016896:Treatment Outcome
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D001562:Benzimidazoles; D001565:Benzoates; D007328:Insulin; D047495:PPAR gamma; D005947:Glucose; D000077333:Telmisartan